In the more than 100 years since paul ehrlich coined the phrase "magische Kugel," or "magic bullet," scientists have been striving to develop targeted therapies for diseases ranging from cancer to Crohn's disease. Although for many years the path toward this goal appeared to be pharmacologic in nature, four decades ago an important deviation was made: the advent of hybridoma technology. This allowed for the production of large quantities of antibodies specific for a single target: monoclonal antibodies. Now, the same molecules that were known to provide long-lasting protection against many infectious diseases had the potential to be harnessed for the treatment of many different diseases.
展开▼
